Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:36:31.637Z.
Calculation as of: 2026-10-06T20:36:31.637Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1e37222dd90dbab5e03bfa1bbf20eaf6e61690ec1e62f49524765e66f30de265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$41.95M
EV/Sales Ratio
N/A
TTM Avg
0.79x
3Y Avg
3.53x
5Y Avg
4.11x
Market Cap
$42.72M
EV/Sales Ratio
1.46x
TTM Avg
3.91x
3Y Avg
2.65x
5Y Avg
3.58x
Market Cap
$42.83M
EV/Sales Ratio
1.25x
TTM Avg
8.61x
3Y Avg
25.49x
5Y Avg
46.59x
Market Cap
$44.02M
EV/Sales Ratio
3.32x
TTM Avg
18.20x
3Y Avg
28.24x
5Y Avg
65.32x
Market Cap
$44.71M
EV/Sales Ratio
1.28x
TTM Avg
4.47x
3Y Avg
4.27x
5Y Avg
5.38x
Market Cap
$44.72M
EV/Sales Ratio
1.08x
TTM Avg
1.15x
3Y Avg
3.38x
5Y Avg
3.26x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $42.26M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $41.95M | N/A | 0.79x | 3.53x | 4.11x |
| Precipio, Inc. (PRPO)vs › | $41.83M | 1.53x | 1.77x | 1.07x | 1.40x |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $42.72M | 1.46x | 3.91x | 2.65x | 3.58x |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.83M | 1.25x | 8.61x | 25.49x | 46.59x |
| CVRx, Inc. (CVRX)vs › | $42.99M | 0.62x | 2.63x | 4.55x | 5.21x |
| DarioHealth Corp. (DRIO)vs › | $44.02M | 3.32x | 18.20x | 28.24x | 65.32x |
| SANUWAVE Health Inc. (SNWV)vs › | $44.71M | 1.28x | 4.47x | 4.27x | 5.38x |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.72M | 1.08x | 1.15x | 3.38x | 3.26x |
| Veru Inc. (VERU)vs › | $39.64M | N/A | 5.31x | 19.81x | 39.98x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
